UNSPSC 51132216: Acetaminophen/calcium carbonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132216 Acetaminophen/calcium carbonate is a Commodity code that in recent state and local solicitations represents a broader pharmaceutical procurement scope—the code's recent activity centers on generic multi-source pharmaceuticals, over-the-counter products, and related pharmaceutical supply chains rather than the acetaminophen/calcium carbonate combination product the code name suggests. State and local health agencies, cooperative purchasing alliances, and county health departments are the primary issuing bodies, with work spanning manufacturer direct supply, wholesaler distribution partnerships, and pharmaceutical inventory procurement for public health programs. Solicitations under this code reflect the shift toward leveraging cooperative purchasing vehicles and direct-to-manufacturer models to manage pharmacy costs and streamline medication distribution to public health facilities.

Recent activity spans Minnesota, Texas, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, requiring manufacturers to supply products through three authorized wholesalers and maintain compliance with cGMP and the Drug Supply Chain Security Act. Seminole County, Florida released an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, though this entry appears mistagged to the acetaminophen code. Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling movement toward bypass of traditional pharmacy benefit managers and wholesalers. Cooperative purchasing vehicles dominate the landscape, with MMCAP spanning multiple states including Oregon and established vendor requirements for EDI capability, cGMP certification, and multi-wholesaler distribution relationships.